Amphastar Pharmaceuticals Q4 Earnings Call Highlights

Core Insights - Amphastar Pharmaceuticals reported a 2% decline in net revenues for 2025, totaling $719.9 million, primarily due to significant declines in legacy products like glucagon, which fell 45% to $14.1 million, and epinephrine, which decreased 9% to $17.1 million, despite strong performance from BAQSIMI and other newer products [4][7][5] Revenue Performance - BAQSIMI generated $185.4 million in revenue for the year, reflecting a 12% year-over-year increase attributed to higher U.S. unit volumes and a shift to direct global distribution [3][5] - Other pharmaceutical product revenue increased by 8% to $62.4 million, driven mainly by sales of albuterol and iron sucrose, which contributed $4.4 million following its August launch [7][2] Financial Metrics - Fourth-quarter net income fell to $24.4 million, or $0.51 per share, down from $38.0 million, or $0.74 per share, a year earlier, with adjusted net income at $34.2 million, or $0.73 per share [10][7] - Operating cash flow for the quarter was approximately $32.9 million, with full-year operating cash flow totaling $156.1 million [10][4] Cost and Margin Analysis - Gross margin remained flat at 47% of revenues, with increased sales of BAQSIMI and iron sucrose offset by pricing declines in glucagon and epinephrine multi-dose vial products [8][6] - General and administrative expenses rose 27% to $16.5 million, primarily due to higher legal expenses and costs related to a new ERP system, while R&D expenses increased by 29% to $23.3 million [9] Future Outlook - For 2026, the company expects consolidated revenue growth in the mid-to-high single-digit range but anticipates lower gross margins due to pricing pressures on high-margin legacy products and a higher mix of lower-margin API sales [6][14] - Management highlighted the launch of ipratropium as a significant growth driver, with expectations for early commercial launch in the second quarter of 2026 [12][11] Pipeline and Expansion - Amphastar is expanding its proprietary pipeline with several programs that represent over $60 billion in addressable market opportunity, including insulin aspart and GLP-1 products expected to commercialize in 2027 [15][16] - The company is also ramping up manufacturing capacity in Rancho Cucamonga, which will quadruple production capacity, financed through operating cash flow [17][18] Market Position and Strategy - Management emphasized the importance of disciplined execution and investment, believing that recent approvals and pipeline progress position the company for continued growth [21]